Track Ipca Laboratories Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.
1 Week returns: 6.59 %
Low
1,791.8
High
1,979.8
1 Month returns: -0.47 %
Low
1,791.8
High
2,020.0
1 Year returns: 53.16 %
Low
1,251.6
High
2,039.3
3 Year CAGR: 25.11 %
Low
960.0
High
2,039.3
5 Year CAGR: 11.38 %
Low
669.8
High
2,039.3
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
Multi-year trends for Ipca Laboratories Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Ipca Laboratories Ltd. Shareholding Pattern
Quarterly breakdown of Ipca Laboratories Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Ipca Laboratories Ltd. shares as reported to NSE and BSE.
Frequently Asked Questions
What is the current share price of Ipca Laboratories Ltd.?
The current share price of Ipca Laboratories Ltd. is ₹ 1,953.30 as of 23 Oct 2026.
What is the market capitalisation of Ipca Laboratories Ltd.?
The market capitalisation of Ipca Laboratories Ltd. stands at ₹ 49,556.00 Cr.
What is the PE ratio of Ipca Laboratories Ltd.?
The Price-to-Earnings (PE) ratio of Ipca Laboratories Ltd. is 37.83 as of the latest trailing twelve months data.
What is the ROE and ROCE of Ipca Laboratories Ltd.?
Ipca Laboratories Ltd. has a Return on Equity (ROE) of 15.20% and a Return on Capital Employed (ROCE) of 16.18% as per the latest financial reports.
What is the 52-week high and low of Ipca Laboratories Ltd.?
The 52-week high of Ipca Laboratories Ltd. is - and the 52-week low is -.
What is the dividend yield of Ipca Laboratories Ltd.?
The dividend yield of Ipca Laboratories Ltd. is 0.31% based on the current market price.
What is the FII and DII holding in Ipca Laboratories Ltd.?
Foreign Institutional Investors (FII) hold 11.52%, Domestic Institutional Investors (DII) hold 35.83% and retail/public investors hold 6.77% of Ipca Laboratories Ltd. shares.
What sector does Ipca Laboratories Ltd. belong to?
Ipca Laboratories Ltd. operates in the Healthcare sector. 75% of analysts have a Buy or Strong Buy rating on Ipca Laboratories Ltd. with a consensus target price of ₹ 2,007.00, implying 2.75% upside from current levels.
What is the beta of Ipca Laboratories Ltd.?
The beta of Ipca Laboratories Ltd. is 0.06, indicating its price volatility relative to the broader market. Over the past 1 year, Ipca Laboratories Ltd. has delivered an absolute return of 50.31%.
What is the RSI of Ipca Laboratories Ltd.?
The 14-day Relative Strength Index (RSI) of Ipca Laboratories Ltd. is 54.91, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.
Stock Analysis
Fundamental analysis overview of Ipca Laboratories Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
Strong price momentum
Price Momentum score of 96.4 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term
What is Price Momentum score?
96.4 / 100
Analysts have been raising forward EPS estimates
Analyst EPS estimate (consensus) for forward EPS has increased by 6.83% in the last 3 months, indicating earnings momentum
What is Earnings upgrade (3M)?
Consistently pays dividend
The company has not missed dividend payments once in the last 9 financial years
What is Dividend streak?
Company is net cash
The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet
What is Net Debt ?
Negative
Expensive and at a premium to industry median P/E
PE TTM of 37.83 indicates that the stock is expensive on a standalone basis and is at a 24.15% premium to industry median P/E
What is P/E Ratio?
Median: 30.47
Value 37.83
-0.82614.73
Low dividend yield
The company has a low dividend yield of 0.31%
What is Dividend yield?
Neutral
Company's earnings are of moderate quality
Earnings quality score of 66.1 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion
What is Earnings quality score?
66.1 / 100
No red flags found!
No significant red flags found in the stock.
Holdings and Presence
Indices and prominent investors with a stake in this stock.
History of Ipca Laboratories Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.
Dividend₹ 6/share
Record date: 7th Aug 2026Ex-date: 7th Aug 2026
Announced on: 29th May 2026
Dividend₹ 2/share
Record date: 5th Aug 2025Ex-date: 5th Aug 2025
Announced on: 29th May 2025
Dividend₹ 2/share
Record date: 27th Nov 2024Ex-date: 27th Nov 2024
Announced on: 24th Oct 2024
Dividend₹ 2/share
Record date: 6th Aug 2024Ex-date: 6th Aug 2024
Announced on: 29th May 2024
Dividend₹ 2/share
Record date: 22nd Nov 2023Ex-date: 22nd Nov 2023
Announced on: 25th Oct 2023
Company Profile
Overview of Ipca Laboratories Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
Ipca Laboratories Limited is an India-based integrated pharmaceutical company. The Company is engaged in manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The Company’s products are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc. and Ipca Pharma Nigeria Ltd.
Ipca Laboratories Limited is an India-based integrated pharmaceutical company. The Company is engaged in manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquin...
Key personnel
Mr. Pabitra Kumar Bhattacharya
President - Operations (API)
Mr. Sunil Ghai
President - Marketing
Dr. Sanjay U. Kapadia
President - Corporate Quality Assurance
Dr. Ashok Kumar
President - Research and Development (Chemicals)
Mr. Shailesh Laul
President - Operations (Formulations)
Mr. Hitesh Kumar Maheshwari
President - Research and Development (Formulations)